Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Nov;53(11):949-52.
doi: 10.1136/thx.53.11.949.

Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

Affiliations
Clinical Trial

Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

A K Simonds et al. Thorax. 1998 Nov.

Abstract

Background: Respiratory failure is the commonest cause of death in patients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effects of nasal intermittent positive pressure ventilation (NIPPV) on survival in symptomatic Duchenne patients with established ventilatory failure.

Methods: Nocturnal NIPPV was applied in 23 consecutive patients with DMD of mean (SD) age 20.3 (3.4) years who presented with diurnal and nocturnal hypercapnia.

Results: One year and five year survival rates were 85% (95% CI 69 to 100) and 73% (95% CI 53 to 94), respectively. Early changes in arterial blood gas tensions following NIPPV occurred with mean (SD) PO2 increasing from 7.6 (2.1) kPa to 10.8 (1.3) kPa and mean (SD) PCO2 falling from 10.3 (4.5) kPa to 6.1 (1.0) kPa. Improvements in arterial blood gas tensions were maintained over five years. Health perception and social aspects of SF-36 health related quality of life index were reported as equivalent to other groups with nonprogressive disorders using NIPPV.

Conclusions: Nasal ventilation is likely to increase survival in hypercapnic patients with Duchenne muscular dystrophy and should be considered as a treatment option when ventilatory failure develops.

PubMed Disclaimer

Comment in

  • Duchenne muscular dystrophy.
    Ishikawa Y, Bach JR. Ishikawa Y, et al. Thorax. 1999 Jun;54(6):564. doi: 10.1136/thx.54.6.562c. Thorax. 1999. PMID: 10866575 Free PMC article. No abstract available.

References

    1. Chest. 1994 Jan;105(1):100-5 - PubMed
    1. Chest. 1993 Dec;104(6):1702-6 - PubMed
    1. Chest. 1994 Feb;105(2):445-8 - PubMed
    1. Thorax. 1994 Feb;49(2):157-61 - PubMed
    1. Anaesthesia. 1994 Apr;49(4):279-83 - PubMed

Publication types